Top Story

FDA approves Solosec oral granules for treatment of bacterial vaginosis

September 18, 2017

Symbiomix Therapeutics announced today that the FDA has approved Solosec 2-g oral granules as the first single-dose oral treatment option for adult women with bacterial vaginosis, the most common gynecologic infection in the U.S., according to a press release.

Solosec (secnidazole, Symbiomix) — a next-generation, 5-nitroimidazole antimicrobial agent — is the first oral antibiotic to be approved for bacterial vaginosis (BV) in more than a decade, according to David L. Stern, CEO of Symbiomix.

In the Journals Plus

New rapid point-of-care test detects TB resistance

September 14, 2017
An investigational assay could accurately detect drug-resistant tuberculosis infections and could be used as a rapid point-of-care test to help clinicians determine the…

IGNITE3 trial completes patient enrollment for eravacycline in cUTIs

September 13, 2017
Tetraphase Pharmaceuticals has completed enrollment in IGNITE3, an ongoing phase 3 clinical trial comparing the efficacy and safety of once-daily IV eravacycline with…

Avycaz reduces risk for death from CRE by 23% compared with colistin

September 8, 2017
In an observational study, patients with carbapenem-resistant Enterobacteriaceae — or CRE — infections who were started on Avycaz had a 23% reduced risk for…
More Headlines »

The Adolescent Patient with Meningococcal Meningitis

No commercial support for this activity.

Although not common, meningococcal meningitis is a serious condition, and can result in extensive morbidity and…
More »

Experts issue recommendations for reducing antibiotic use in livestock

September 5, 2017
A new report authored by 12 antibiotic resistance experts outlines policy recommendations that aim to address the…
More »
Resource Centers
ASM Microbe

ASM Microbe

Meeting News

VIDEO: ID support in ASPs has larger impact on antibiotic use

November 6, 2016
More »